<DOC>
	<DOCNO>NCT00339157</DOCNO>
	<brief_summary>1 . Main objective : To test efficacy anakinra treatment child young adult corticosteroid-resistant -dependent Systemic-Onset Juvenile Idiopathic Arthritis ( SO-JIA ) 2 . Design : Double blind , randomize trial test efficacy one month Anakinra treatment versus placebo ( 2 group 12 patient ) . All patient treat anakinra follow 11 month dose corticosteroid gradually taper ( = descriptive part trial ass tolerance efficacy 12 month ) . 3 . Hypothesis : 70 % significant improvement 1 month Anakinra-treated patient versus 10 % placebo group . 4 . Main inclusion criterion : diagnosis SO-JIA ( Durban consensus conference criterion ) , age : 2 20 year inclusion , active , corticosteroid-resistant -dependent disease , previous IL-1ra treatment .</brief_summary>
	<brief_title>Interleukin-1 Receptor Antagonist ( IL-1RA ) ( ANAKINRA ) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>SOJIA ( Edmonton 's revision Durban 's consensus conference criterion ) Age : least 2 year less 20 year treatment initiation Disease duration least 6 month Failure corticosteroid treatment requirement corticosteroid treatment daily dose equal 0.3 mg/kg ( 10 mg patient whose weight 34 kg ) Active severe systemic symptom and/or arthritis assess experienced pediatric Rheumatologists , least 3 follow criterion assess Giannini 's coreset item : 1 ) physician global assessment disease activity least 20/100 ; 2 ) parent/patient assessment disease effect overall wellbeing least 20/100 ; 3 ) functional disability Children Health Assessment Questionnaire ( CHAQ , Ref [ 9 ] ) score equal high 0.375/3 ; 4 ) 2 joint active arthritis 5 ) 2 joint nonirreversible limited range motion ( irreversible limit range motion define radiological evidence irreversible joint damage ankylosis ) 6 ) erythrocyte sedimentation rate ( ESR ) equal high 20 . In absence diseaserelated fever , either CRP first hour ESR upper limit normal value treatment effect systemic part disease objectively evaluate . Patients polyarthritis ( least 5 joint inflammation and/or limitation motion ) eligible study least 50 % affected joint present radiological evidence irreversible damage . Informed consent sign parent person legally responsible patient patient less 18 , patient old enough Teenager girl young woman childbearing potential must use contraceptive method ( include abstinence tuberculin test perform Day 1 must either negative positivity must relate previous immunization normal intensity accord investigator 's judgment Previous treatment IL1Ra intraarticular injection change dose nonsteroidal antiinflammatory drug corticosteroids 4 week precede initiation anakinra treatment Treatment another immunosuppressive diseasemodifying drug could stop inclusion ( duration depend drug pharmacokinetic property ) Contraindication use anakinra include ongoing active infection allergy E Coli 's derivate component drug Previous history malignancy heart insufficiency Patients asthma require previously assess pneumonologist Obvious need therapeutic intervention study completion surgery , intraarticular injection , life vaccine administration Any following : leucocyte count &lt; 3.6 x 10e9/L , polymorphonuclear neutrophil count &lt; 1.5 x 10e9/L , platelet &lt; 150 000/mm3 , serum creatinin &gt; 1.5 upper limit normal range age , serum alanine aspartate transaminase &gt; 2 time upper limit normal range , serum bilirubin &gt; 2 time upper limit normal range</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>IDIOPATHIC JUVENILE ARTHRITIS</keyword>
	<keyword>PEDIATRICS</keyword>
	<keyword>ORPHAN DISEASE</keyword>
	<keyword>INTERLEUKIN - 1</keyword>
	<keyword>RECEPTORS , INTERLEUKINS</keyword>
	<keyword>ANTAGONISTS</keyword>
</DOC>